PRTK Market Cap History
Below is a table of the PRTK market cap history going back to 10/24/2014:

Date PRTK Market Cap
10/24/201433.53M
10/31/2014230.69M
2/28/2015421.44M
5/6/2015490.31M
7/31/2015441.84M
11/6/2015322.77M
2/29/2016269.06M
4/29/2016241.62M
7/29/2016291.22M
10/31/2016242.12M
2/28/2017363.08M
4/28/2017589.56M
7/28/2017563.55M
10/31/2017597.94M
2/28/2018411.91M
4/30/2018338.08M
7/31/2018320.47M
10/31/2018239.45M
2/28/2019210.06M
4/30/2019178.61M
7/31/2019105.09M
2/28/2011177.54M
10/31/2019102.86M
2/28/2020201.81M
4/30/2020176.41M
7/31/2020198.34M
10/30/2020217.71M

Also see: PRTK Shares Outstanding History
and PRTK YTD Return
PRTK Historical Market Cap:
+36.43% CAGR
PRTK Historical Market Cap: +36.43% CAGR

Mouse over chart for data details
10/24/2014 ...10/30/2020
Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for diseases or other public health threats for civilian, government and military use. Co.'s U.S. Food and Drug Administration approved commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens. SEYSARA® (sarecycline) is being marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. We show 27 historical shares outstanding datapoints in our PRTK shares outstanding history coverage, used to compute PRTK market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing PRTK market cap history over the course of time is important for investors interested in comparing PRTK's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of PRTK versus a peer is one thing; comparing PRTK market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like PRTK can fluctuate over the course of history. With this page we aim to empower investors researching PRTK by allowing them to research the PRTK market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for PRTK:
PRTK SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Paratek Pharmaceuticals (PRTK) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

PRTO Market Cap History
PSTI Market Cap History
PTCT Market Cap History
PTGX Market Cap History
PTI Market Cap History
PTIE Market Cap History
PTLA Market Cap History
PTX Market Cap History
PULM Market Cap History
QDEL Market Cap History
More Healthcare companies »

 

PRTK Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2020, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.